Option chain shows key data for Imunon's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Imunon.

Imunon (NASDAQ:IMNN) Stock, Option Chain

Imunon

Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.

vaccine-4892059

News

IMNN

Imunon shares are trading lower by 61% during Wednesday&#39;s session. The company announced a $10 million registered direct offering.

Why Imunon (IMNN) Stock Is Down 60% Today

Wall Street bull

Earnings

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

FGEN

FVRR

MSFT

PEPG

POWL

Nasdaq Surges Over 3%; Powell Industries Shares Spike Higher

Wall Street, US stocks

NCNC

NUZE

PMEC

Dow Jumps Over 200 Points; Kraft Heinz Shares Gain After Q2 Earnings

Imunon Inc

Barclays analyst Alex Scott maintains Arthur J. Gallagher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) with a Equal-Weight and raises the price target from $300 to $308.

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Arthur J. Gallagher, Raises Price Target to $308

Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares are trading higher on Thursday. The company announced it submitted a <a href="https://www.benzinga.com/pressreleases/24/11/b42099063/super-micro-computer-inc-nasdaq-non-compliance-update">compliance plan to the Nasdaq</a>.
What Happened: After the market close on Wednesday, Super Micro said it submitted a compliance plan to the Nasdaq after receiving a notification letter that it was not in compliance with the Nasdaq&#8217;s timely filing rule. The plan was submitted on Monday with respect to supporting the company&#8217;s request for an extension to regain compliance.
Super Micro said in the compliance plan that it believes it will be able to file both its annual report for the fiscal year ended June, 30 2024 and its quarterly report for the period ended Sept. 30, 2024 within the discretionary period that can be granted by the Nasdaq.
See Also: <a href="https://www.benzinga.com/news/earnings/24/11/42109965/baidus-q3-earnings-revenue-slides-weak-online-ads-market-impact-margins">Baidu&#8217;s Q3 Earnings: Revenue Slides, Weak Online Ads Market Impact Margins</a>
The update comes after the company&#8217;s independent auditor resigned at the end of October over&nbsp;<a href="https://www.benzinga.com/quote/SMCI" target="_blank" rel="noreferrer noopener">governance and transparency concerns</a>. 
Super Micro on Monday announced that it <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42069253/supermicro-stock-is-rising-tuesday-whats-going-on">appointed BDO USA</a> as its new independent auditor, effective immediately.
&#8220;BDO is a highly respected accounting firm with global capabilities.&nbsp;This is an important next step to bring our financial statements current, an effort we are pursuing with both diligence and urgency,&#8221; said&nbsp;Charles Liang, president and CEO of SuperMicro.
Super Micro has faced significant selling pressure since the company&#8217;s auditor raised concerns. The stock traded all the way down to around $17.25 per share last week before bouncing back. Super Micro shares are now up more than 43% over the past five trading sessions.
SMCI Price Action: Super Micro shares were up 5.23% at $27.18 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Movers

SMCI

Super Micro Computer Stock Is Rallying Thursday: What's Going On?

LAZR

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Piper Sandler analyst Adam Butler assumes Farmers National Banc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FMNB#NASDAQ">FMNB</a>) with a Neutral rating and announces Price Target of $17.

Initiation

FMNB

Piper Sandler Assumes Farmers National Banc at Neutral, Announces Price Target of $17

Barclays analyst Alex Scott maintains Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) with a Overweight and raises the price target from $394 to $440.

Barclays Maintains Overweight on Aon, Raises Price Target to $440

Agrify Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGFY#NASDAQ">AGFY</a>) shares are trading lower by 23.9% to $29.50 Thursday morning after the company announced it secured approximately $25.9 million through a <a href="https://www.benzinga.com/pressreleases/24/11/g42108171/agrify-announces-25-9-million-non-brokered-private-placement">non-brokered private placement</a>.
What Happened: The deal, priced at $22.30 per share, involves securities purchase agreements with institutional and accredited investors. The proceeds will support general corporate purposes, including working capital and business development.
The private placement, expected to close on November 21, includes participation from Chairman and Interim CEO Benjamin Kovler, who purchased 10,000 shares at $38.76 each in accordance with Nasdaq requirements.
Kovler emphasized the strategic significance of the funding, calling it a &#8220;strong move&#8221; for the company and shareholders. &#8220;We plan to channel this capital into areas within our expertise to maximize shareholder value,&#8221; he said, highlighting optimism around cannabis and hemp consumer trends. 
Kovler also confirmed progress on the company&#8217;s pending Señorita transaction, which is anticipated to close by year-end.
Read Also: <a href="https://www.benzinga.com/general/market-summary/24/11/42100955/the-u-s-cannabis-strategy-no-ones-talking-about-inside-canopys-300m-plan">The U.S. Cannabis Strategy No One&#8217;s Talking About: Inside Canopy&#8217;s $300M Plan</a>
<h2 class="wp-block-heading">Should I Sell My AGFY Stock?</h2>
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
For analysis tools, charting data and access to exclusive stock news, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a> 
AGFY has a 52-week high of $42.00 and a 52-week low of $2.71.

AGFY

Why Agrify (AGFY) Stock Is Getting Hammered

CGNT

Cognyte Secures $2M+ Follow-On Order From Leading North American Law Enforcement Agency, Bringing Total Investment To $3M As Agency Replaces Incumbent Provider For Enhanced Threat Detection And Operational Intelligence

WIIM

Warner Music Group shares are trading lower after the company reported worse-than-expected Q4 EPS results.

KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) shares are trading higher premarket on Thursday. The company led a $370 million growth investment in Lighthouse, a commercial intelligence platform<a href="https://www.benzinga.com/pressreleases/24/11/b42104948/lighthouse-announces-370-million-series-c-investment-led-by-kkr-to-accelerate-platform-innovation-" target="_blank" rel="noreferrer noopener"> for the travel and hospitality industry</a>.
This funding will propel Lighthouse&#8217;s efforts to transform commercial strategy within the $15 billion travel and hospitality technology sector. 
The investment will be allocated towards further product innovation, strategic acquisitions, and expanding Lighthouse's global presence.
Notably, KKR has a proven track record of investing $23 billion in technology-focused growth companies since 2010, which will help Lighthouse expand globally.
Sean Fitzpatrick, CEO of Lighthouse said, &#8220;This investment by KKR significantly accelerates our ability to enhance our commercial platform through expanded AI capabilities and additional data sets, enabling us to better serve our existing customers while continuing to expand across the hospitality market.&#8221;
Yesterday, KKR launched the second stage of its tender offer for FUJI SOFT INCORPORATED shares and share options, which started on November 20, 2024, and will <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42083136/kkr-commences-second-tender-offer-for-fuji-soft" rel="noreferrer noopener">run until December 19, 2024</a>.
The tender offer price is 9,451 yen per common share and varies for share options, with prices set at 1,197,200 yen for the 5th Series, 1,059,800 yen for the 6th Series, and 293,200 yen for the 7th Series.
Investors can gain exposure to KKR via&nbsp;FM Focus Equity ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMCX#NYSE">FMCX</a>) and&nbsp;EA Series Trust WHITEWOLF Publicly Listed Private Equity ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/LBO#BATS">LBO</a>).
Price Action: KKR shares are up 1.19% at $153.99&nbsp;premarket at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/ma/24/11/42025534/deal-dispatch-shell-unilever-and-more-are-on-the-sell-side-the-onion-makes-alex-jones-cry-foul" target="_blank" rel="noreferrer noopener">Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul</a></li>
</ul>

Equities

FMCX

KKR Inks $370 Million Investment, Propels Lighthouse's Global Hospitality Ambitions

Roth MKM analyst Bill Kirk maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Neutral and lowers the price target from $157 to $131.

Roth MKM Maintains Neutral on Target, Lowers Price Target to $131

CETY

Clean Energy Technologies shares are trading higher after the company announced a strategic partnership with METIS Power to develop advanced microgrid solutions for AI data centers and cryptocurrency mining operations.

GRAB

Grab Holdings shares are trading lower after China Renaissance downgraded the stock from Buy to Hold.

Copa Holdings shares are trading lower after the company reported worse-than-expected Q3 financial results.

Summary
In summary, it has become clear that the current Greenfire Board, in the face of poor operational performance, a declining share price and blatant self-dealing, has resorted to desperate corporate lawfare maneuvers to entrench themselves despite overwhelming evidence that their shareholders and the market has lost confidence in them.
Fortunately, Greenfire shareholders have another option. WEF was attracted to Greenfire likely for the same reason as many of its fellow shareholders: Greenfire owns a high-quality asset, but the company's value is currently clouded by mismanagement and a dysfunctional Board. WEF has a track record of creating value by simplifying complex corporate situations so that the underlying value of the assets can shine through, and it is confident it can once again do so with Greenfire.
WEF is&nbsp;requesting&nbsp;that&nbsp;the&nbsp;Board call a meeting of Greenfire shareholders to replace the current Board of&nbsp;four with six highly-qualified directors (the "Shareholder Nominees") who bring significant oil and gas, operational, public company, capital markets, mergers and acquisitions and financial experience.&nbsp;WEF requests that the Meeting be held promptly, and in any event by no later than January 2025.
Finally, contrary to Greenfire's baseless claims in its November 20, 2024 press release, WEF has no intention of proposing a combination of Greenfire and Strathcona at this time. Furthermore, even if it did, shareholders should rest assured that any such transaction would be subject to the approval of the majority of disinterested (i.e. non-WEF) shareholders (at both Greenfire and Strathcona), under Multilateral Instrument 61-101&nbsp;- Protections for Minority Shareholders. Moreover, contrary to Greenfire's claims, all six of WEF's nominees are considered independent under applicable securities laws.

Management

The Collective Beneficial Owners Of ~43% Of The Issued And Outstanding Shares Of Greenfire Resources And Greenfire's Largest Shareholder, Announce That They Have Requisitioned A Special Meeting Of Holders Of Common Shares For The Purpose Of Replacing The Current Board Of Directors

Barclays analyst Brian Morton downgrades National Bank of Canada (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NA#TSX">NA</a>) from Overweight to Equal-Weight and raises the price target from C$130 to C$140.

Downgrades

TSX:NA

Barclays Downgrades National Bank of Canada to Equal-Weight, Raises Price Target to C$140

KinderCare Learning shares are trading higher. The company reported Q3 financial results.

Biotech

General

ALPS ETF Trusthen & Steers Global Realty Majors ETF

GRI Bio Highlights GRI-0621's Potential To Reduce Inflammation And Hepatic Fibrosis In Idiopathic Pulmonary Fibrosis, With Positive Preclinical Data Presented At AFDD Summit And Phase 2 Topline Data Expected In Q2 2025

Dream Finders Homes shares are trading higher after the company announced it will join the S&P SmallCap 600 and replace Haynes.

$BTC

Clean Energy Technologies Partners With METIS Power To Deliver Advanced Microgrid Solutions For AI Data Centers And Crypto Miners, Combining Waste Heat Recovery And Scalable Energy Systems To Enhance Efficiency And Sustainability

Cantor Fitzgerald analyst Li Watsek reiterates Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) with a Overweight.

Reiteration

KURA

Cantor Fitzgerald Reiterates Overweight on Kura Oncology

Imunon, Inc. (IMNN) Q2 2024 Earnings Call Transcript

Imunon files to sell up to 5M shares

The latest announcement is out from Imunon ( ($IMNN) ). Imunon, Inc. has appointed Susan Eylward as its new General Counsel and Corporate Secretary...

Imunon Welcomes Susan Eylward as General Counsel, Strengthens Leadership Team

IMUNON (IMNN) announced the acceptance of a late-breaking presentation featuring new clinical data from the Phase 2 OVATION 2 Study of IMNN-001, it...

Imunon to present Phase 2 data of IMNN-001

Imunon Q3 2024 Earnings Preview

Imunon GAAP EPS of -$0.34 beats by $0.06

"The third quarter was a period of important milestones and outstanding progress for IMUNON (IMNN), driven largely by presentation of highly compel...

Imunon reports Q3 EPS (34c), consensus (40c)

IMUNON (IMNN) announced the presentation of new clinical data from the recently completed Phase 2 OVATION 2 Study of IMNN-001, its investigational ...

Imunon presents data from Phase 2 OVATION 2 clinical trial

Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript

Imunon, Inc. ( ($IMNN) ) has released its Q3 earnings. Here is a breakdown of the information Imunon, Inc. presented to its investors. Imunon, Inc....

Imunon, Inc. Reports Q3 2024 Earnings and Progress

Press Releases

IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024

IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update

IMUNON to Host R&D Day on September 18th

IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

Comments

Imunon

Imunon (IMNN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga